Cite

HARVARD Citation

    D'Urzo, A. et al. (n.d.). P252 Once-daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial. Thorax. p. A170. [Online]. 
  
Back to record